Synonyms
Status
Molecule Category UNKNOWN
UNII CR743OME9E
EPA CompTox DTXSID90211380

Structure

InChI Key GDTQLZHHDRRBEB-UHFFFAOYSA-N
Smiles CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C
InChI
InChI=1S/C22H26N6O2/c1-4-9-23-22(30)17-11-28-19(14(17)3)20(24-12-25-28)27-18-10-15(6-5-13(18)2)21(29)26-16-7-8-16/h5-6,10-12,16H,4,7-9H2,1-3H3,(H,23,30)(H,26,29)(H,24,25,27)

Physicochemical Descriptors

Property Name Value
Molecular Formula C22H26N6O2
Molecular Weight 406.49
AlogP 3.12
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 7.0
Polar Surface Area 100.42
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 30.0

Bioactivity

Mechanism of Action Action Reference
MAP kinase p38 alpha inhibitor INHIBITOR PubMed PubMed
Protein: MAP kinase p38 alpha

Description: Mitogen-activated protein kinase 14

Organism : Homo sapiens

Q16539 ENSG00000112062
Assay Description Organism Bioactivity Reference
Inhibition of human ERG at 30 uM Homo sapiens 16.0 %
Inhibition of bacterially expressed p38alpha pretreated for 10 mins measured after 45 mins None 13.0 nM
Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production treated 30 mins before LPS challenge measured after 6 hrs by ELISA Homo sapiens 50.0 nM
Antiinflammatory activity in BALB/c mouse serum assessed as inhibition of LPS-induced TNFalpha production at 5 mg/kg, po administered 2 hrs before LPS challenge measured after 90 mins by ELISA Mus musculus 89.0 %
Antiinflammatory activity in BALB/c mouse serum assessed as inhibition of LPS-induced TNFalpha production at 5 mg/kg, po administered 6 hrs before LPS challenge measured after 90 mins by ELISA Mus musculus 78.0 %
Inhibition of p38beta (unknown origin) Homo sapiens 62.0 nM
Inhibition of paw swelling in Lewis rat adjuvant arthritis model assessed as reduction in hind paw volume at 1 mg/kg, po bid beginning on day 11 post adjuvant challenge by volume displacement plethysmometry method relative to control Rattus norvegicus 27.0 %
Inhibition of paw swelling in Lewis rat adjuvant arthritis model assessed as reduction in hind paw volume at 3 mg/kg, po bid beginning on day 11 post adjuvant challenge by volume displacement plethysmometry method relative to control Rattus norvegicus 35.0 %
Inhibition of P38alpha MAPK (unknown origin) Homo sapiens 13.0 nM

Cross References

Resources Reference
ChEMBL CHEMBL1230065
DrugBank DB12696
FDA SRS CR743OME9E
Guide to Pharmacology 7838
PDB 38P
PubChem 10409068
SureChEMBL SCHEMBL254996
ZINC ZINC000036475284